Obermatt
See Similar Stocks →

Atea Pharmaceuticals

NSQ:AVIR · US04683R1068
PharmaceuticalsSmall

360° View

5
Price/Sales43
Price/Earnings28
Price/Book48
Dividend Yield1
Revenue Growth1
Profit Growth37
Capital Growth8
TSR 52w38
Leverage93
Liquidity67
Refinancing15
Combined20
Analyst Opinions12
Pro Holdings61
Opinion Changes50
Market Pulse6

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2012
Employees51
Websiteateapharma.com
ISINUS04683R1068
Last UpdateApr 2, 2026
Index & Theme
RespiratoryInfectious DiseasesHepatologyBiopharmaHealth CarePharmaceutical

Description

Atea Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company. The company is leveraging a deep understanding of antiviral drug development, medicinal chemistry, biochemistry, and virology to discover, develop, and commercialize nove…

Analysis

Atea Pharmaceuticals's 360° View rank of 5 places it among the weakest overall — better than 5% of its true peers.

It's lagging on growth (12) and expensive versus peers (10). On safety it is financially sound (70), and the market shows skeptical sentiment (17). Taken together, its Combined rank of 20 reads as among the weakest overall.

360° rank · history

1007550250
5
2023202420252026

All-time high

37

Jan 2025

All-time low

5

Jun 2026

Average rank

22

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
43
3
5
6
Price/Earnings
28
89
89
45
Price/Book
48
88
89
77
Dividend Yield
1
1
1
1
Value (overall)
10
33
38
23

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Atea Pharmaceuticals with its peers
Esperion Therapeutics
NMQ:ESPR
9
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
RAPT Therapeutics
NMQ:RAPT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Vir Biotechnology
NSQ:VIR
56
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Kymera Therapeutics
NMQ:KYMR
30
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Assembly Biosciences
NSQ:ASMB
33
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Cytokinetics
NSQ:CYTK
13
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →